Thursday, November 13, 2025 

12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET

Register 

Cost: FREE for SIDP Members! $10 for non-member attendees

Oftentimes, optimal dosing of antibiotics for obese patients is not specified in product labeling and can be controversial. Due to the obesity epidemic in the United States, it is important for pharmacists to identify pharmacokinetic/pharmacodynamic changes that occur in obesity, the risks of inappropriate dosing, and agents for which optimal dosing may be different in obese patients.

Historically, adult renal dosing adjustments for antimicrobials have been based on the 1976 published Cockcroft-Gault estimated creatinine clearance (CG eCrCL) equation. However, newer antimicrobial package inserts now have renal dosing recommendations based on other race-free equations for estimated glomerular filtration rate (eGFR), and the US Food and Drug Administration (FDA) recommends pharmaceutical industry to use eGFR rather than CG eCrCL for pharmacokinetic studies. Additionally, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) now support the use of eGFR. It is important for pharmacists to understand the rationale for the transition from CG eCrCL to race-free eGFR equations for estimating kidney filtration function  Pharmacists must be able to appropriately implement use of the eGFR equation to effectively adjust antimicrobial dosing to optimize patient outcomes.

This program provides an in-depth review of current guidelines, evidence-based strategies, and real-world clinical scenarios to enhance ability of the learner to assess renal function accurately and adjust antimicrobial dosing accordingly. By the end of the activity, participants will be equipped to make informed, patient-specific dosing decisions that improve antimicrobial efficacy while minimizing toxicity and resistance development.

Target Audience:

This education activity was planned to meet the needs of pharmacists who practice in clinical settings where evaluating renal function and optimizing antimicrobial therapy are essential to patient care.

• Compare and contrast Cockroft Gault (CG), MDRD, and CKD-EPI methods for estimation of renal function in adult patients
  
• Appraise current literature regarding recommendations for evaluating renal function
  
• Apply newly recommended renal function assessment methods to patient-specific cases to optimize antimicrobial dosing

Faculty:

Mark Biagi, PharmD
Clinical Assistant Professor
Retzky College of Pharmacy
University of Illinois Chicago 
Chicago, IL

Accreditation:

Pharmacist

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0672-0000-25-027-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Application
ACPE Activity Fee: SIDP Member: Free / Non-Member: $10

To receive CE credit, participants must view the CE content, complete a post-test with a passing score of 70% or greater, and complete an evaluation. Proof of completion will be submitted to NABP CPE Monitor.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.

Funding:

This activity is provided by SIDP. No external funding was received for this activity.

Disclosures:

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:

• Dr.  Biagi's disclosures will be announced prior to the start of the activity.
• SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.
• Presentation title and objectives were written by the planning committee and enhanced by AI. All enhancements were reviewed by a human.

Disclaimer:

Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.

The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.